BIOMODEX Technology Enables New Milestone in Interventional Cardiology

BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS™ (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL.

Physicians at the Montreal Heart Institute in Montreal, Quebec recently rehearsed the full procedure of a Left Atrial Appendage Occlusion (LAAO) for the first time in North America using a bio-realistic haptic simulator. This breakthrough was achieved by Dr. Reda Ibrahim (interventional cardiologist), Dr. Blandine Mondesert (electrophysiologist), and Dr. Walid Ben Ali (cardiac surgeon) utilizing a 3D-printed replica of the patient’s heart. This replica is part of a novel simulator that delivers realistic catheter navigation, haptic feedback, transesophageal echography, and fluoroscopic imaging.

“Rehearsing a specific case was very helpful—especially one in which we used innovative technologies like the new Abbott Steerable Delivery Sheath for the Amplatzer Amulet occluder, and the transseptal VersaCross Baylis System,” said Dr. Ibrahim. “This realistic simulation allowed us to maximize procedural success and safety.”

For this case, Biomodex printed a 3D patient-specific cardiac anatomy based on the patient’s own CTA images. Models are made of advanced materials that simulate the biomechanical characteristics and haptic feedback of the anatomy. Furthermore, the LAACS station replicates blood flow and viscosity and is ultrasound compatible. The simulation is intended to boost physician confidence, reduce operating times, and decrease the risk of complications.

Cardiovascular transcatheter therapies have transformed the treatment landscape, expanding options for patients with structural heart disease.

“Rehearsing these novel approaches using a patient-specific anatomical model is intended to better prepare physicians and potentially improve patient outcomes,” said Ziad Rouag, President and Chief Executive Officer of Biomodex. “It was an honor to support Dr. Ibrahim and his team.”

The rehearsal and subsequent live patient procedure were performed and recorded at the Montreal Heart Institute. Dr. Ibrahim and his team will present their live case at TVT 2021: The Structural Heart Summit on July 22 from 9:30am to 10:10am EDT (LAA Live Case #20: Update of Left Atrial Appendage Occlusion). To register, visit here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.